By Dr. David C. Pate It’s been a full and eventful year on all levels, local to global and everything in between, in health care and in so many other areas of our economy and business activity. We’ve seen considerable change in government, in payer structures, on the regulatory front … I am hard-pressed to […]
One-fourth of all healthcare products today are temperature sensitive and that number is growing. The use of biologics has also increased dramatically, with more than 900 biologics for over 100 diseases. That adds up to some formidable supply chain challenges. But companies can overcome them and thrive by adopting best practices noted in this white […]
Jack Whelan is a 8 yr survivor of a rare, incurable blood cancer moving from a career IT Research Analyst to Research Advocate. Using business communications and research skills from his career as a Wall Street Research Analyst in Information Technology (IT) and career Sales VP in IT, he now helps bridge the communications gap […]
This video is Part One of our enlightening discussion with Dr. Pate. Click Here to watch the entire interview. Healthcare Executives Network interviews Dr. David C. Pate, President & CEO St. Luke’s Health System […]
It’s estimated that the average cost of developing a new drug has increased from $1 billion in 2010 to $1.1 billion in 2012. A big part of the cost can be attributed to clinical research, which typically lasts at least eight-and-a-half years. Given the enormous cost, time, and effort involved in clinical research, sponsors and […]
What is value in today’s oncology market? This is a question dividing pharma, payers, providers, and patients. At a time when drug reimbursement is a continuously changing landscape, it is more important than ever to align all stakeholders on a common definition. Back for a 7th year, eyeforpharma Oncology Leadership Summit (June 16-17) brings together […]
Dr. Evan Levine discusses his 10 step plan on how to fix the pharmaceutical industry. Top ten List of Dr. Levine: Encourage Research. Require Pharma Cos. with foreign HQ cannot charge more in U.S. than in other countries. Patent on any drug starts on the day the patent is given […]
The recent webinar “Demonstrating Value in Price” turned out to be one of the hottest debates between key oncology stakeholders in 2016! Throughout the discussion your industry peers asked a plethora of vital questions on pricing & value frameworks… In response, eyeforpharma has developed a paper compiling industry research, top insights from the webinar, and […]
